Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size

European Journal of Pharmacology

Volumn 467, Issue 1-3, 2003, Pages 163-168

  Sbarouni, Eftihia ^a   Iliodromitis, Efstathios K ^a   Bofilis, Elias ^a   Kyriakides, Zenon S ^a   Kremastinos, Dimitrios Th ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Estrogen; Hypercholesterolemia; Infarct size; Progestin; Raloxifene

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HEART PROTECTION; HYPERCHOLESTEROLEMIA; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RABBIT; STATISTICAL SIGNIFICANCE;

EID: 0037466497     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01627-3     Document Type: Article

References (49)

1. Adams M.R., Kaplan J.R., Manuck S.B., Koritnik D.R., Parks J.S., Wolfe M.S., Clarkson T.B. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Arteriosclerosis. 10:1990;1051-1057.
2. Adams M.R., Register T.C., Golden D.L., Wagner J.D., Williams K.J. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;217-221.
3. Barrett-Connor E.et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA. 287(7):2002;847-857.
4. Bjarnason N.H., Haarbo J., Byrjalsen I., Kauffman R.F., Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation. 96:1997;1964-1969.
5. Bjarnason N.H., Haarbo J., Byrjalsen I., Alexandersen P., Kauffman R.F., Christiansen C. Raloxifene and estrogen reduces progression of advanced atherosclerosis - a study in ovariectomized, cholesterol-fed rabbits. Atherosclerosis. 154:2001;97-102.
6. Blum A., Schenke W.H., Hathaway L., Mincemoyer R., Csako G., Waclawiw M.A., Cannon R.O. Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women. Am. J. Cardiol. 86:2000;892-895.
7. Clarkson T.B., Anthony M.S., Jerome C.P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 83:1998;721-726.
8. Cushman M., Legsult C., Barrett-Connor E., Stefanick M.L., Kessler C., Judd H.L., Sakkinen P.A., Tracy R.P. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Circulation. 100:1999;717-722.
9. Delmas P.D., Bjarnanson N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337:1997;1641-1647.
10. De Valk-de Roo G., Stehouwer C.D.A., Mijatovic V., Kluft C., Kenemans P., Cohen F., Watts S., Netelenbos C. Raloxifene and estrogen reduces major cardiovascular risk factors in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 19:1999;2993-3000.
11. Figtree G.A., Lu Y., Webb C.M., Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation. 100:1999;1095-1101.
12. Grady D., Rubin S.M., Petitti D.B., Fox C., Black D., Ettinger B., Ernster V., Cummings S. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 117:1992;1016-1037.
13. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willet W.C., Rosner B., Spazer F.E., Hennehens C.H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335:1996;453-461.
14. Guetta V., Cannon R.O. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation. 93:1996;1928-1937.
15. Haarbo J., Leth-Espensen P., Stender S., Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J. Clin. Invest. 87:1991;1274-1279.
16. Hale S.I., Birnbaum Y., Kloner R.A. β-Estradiol, but not a-estradiol, reduces myocardial necrosis in rabbits after ischemia and reperfusion. Am. Heart J. 132:1996;258-262.
17. Hanke H., Hanke S., Finking G., Muhic-Lohrer A., Muck A.O., Schmahl F.W., Haasis R., Hombach V. Different effects of estrogen and progesterone on experimental atherosclerosis in female versus male rabbits. Circulation. 94:1996;175-181.
18. Hayashi T., Fukuto J.M., Ignarro L.J., Chaundhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc. Natl. Acad. Sci. 89:1992;11259-11263.
19. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E., Furgerg C.D., Kowalchuk G.J., Stuckey T.D., Rogers W.J., Givens D.H., Waters D. Effect of estrogen replacement on the progression of coronary artery atherosclerosis. N. Engl. J. Med. 343:2000;522-529.
20. Herrington D.M., Pudder B.E., Riley W.A., Thuren T.Y., Brosnihan K.B., Brinton E.A., MacLean D.B. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 20(6):2000;1606-1612.
21. Holm P., Korsgaard N., Shalmi M., Andersen H.L., Hougaard P., Skouby S.O. Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. J. Clin. Invest. 100:1997;821-828.
22. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
23. Kaufman R.F., Bensch W.R., Roudebush R.E., Cole H.W., Bean J.S., Phillips D.L., Monroe A., Cullinan G.J., Glaseback A.L., Bryant H.U. Hypocholesterolemic activity of raloxifene (LY 139481): pharmacological characterization as a selective estrogen receptor modulator. J. Pharmacol. Exp. Ther. 280:1997;146-153.
24. Keaney J.F., Swaery G.T., Aiming X., Nicolosi R.J., Loscalzo J., Foxall T.L., Vita J.A. 17-β estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation. 89:1994;2251-2259.
25. Kim Y.D., Chen B., Beauregard J., Kouretas P., Thomas G., Farhat M.Y., Myers A.K., Lees D.E. 17β-estradiol prevents dysfunction of canine coronary endothelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion. Circulation. 94:1996;2901-2908.
26. Kremastinos D., Bofilis E., Karavolias G., Papalois A., Kaklamanis L., Iliodromitis E. Preconditioning limits myocardial infarct size in hypercholesterolemic rabbits. Atherosclerosis. 150:2000;81-89.
27. Levine R.L., Chen S.J., Durand J., Chen Y.F., Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation. 94:1996;2221-2227.
28. Lundeen S.G., Carver J.M., McKean M.L., Winneker R.C. Characterization of the ovariectomised rat model for the evaluation of estrogen effects on plasma cholesterol levels. Endocrinology. 138:1997;1552-1558.
29. Mc Hugh N.A., Cook S.M., Schairer J.L., Merill G.F. Ischemia and reperfusion-induced ventricular arrhythmias after brief ischemia-reperfusion. Am. J. Physiol. 268:1995;H2569-H2573.
30. Miller V.M., Vanhoutte P.M. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am. J. Physiol. 261:1991;R1022-R1027.
31. Miyagawa K., Rosch J., Stanczyk F., Hermesmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat. Med. 3:1997;324-327.
32. Node K., Kitakaze M., Kosaka H., Minamino T., Funaya H., Hori M. Amelioration of ischemia and reperfusion-induced myocardial injury by 17β-estradiol. Circulation. 96:1997;1953-1963.
33. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91:1993;2546-2551.
34. Oparil S., Levine R.L., Sui-Juan C., Durand J., Chen Y.F. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation. 95:1997;1301-1307.
35. Ridker P.M., Hennekens C.H., Rifai N., Buring J.E., Manson J.E. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 100:1999;713-716.
36. Saitta A., Altavilla D., Cucinotta D., Morabito N., Frisina N., Corrado F., DãAnna R., Lasco A., Squadrito G., Gaudio A., Cancellieri F., Arcoraci F., Squadrito F. Randomized, double-blind, placebo-controlled study on the effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 21(9):2001;1512-1519.
37. Sbarouni E., Iliodromitis E., Bofilis E., Kyriakides Z., Kremastinos D. Short-term estrogen reduces myocardial infarct size in oophorectomized female rabbits in a dose-dependent manner. Cardiovasc. Drugs Ther. 12:1998;457-462.
38. Shlipak M.G., Angeja B.G., Go A.S., Frederick P.D., Canto J.G., Grady D. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation. 104(19):2001;2256-2259.
39. Smith P.J.W., Ornatsky O., Stewart D.J., Picard P., Dawood F., Wen W.H., Liu P.P., Webb D.J., Monge J.C. Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rat. Circulation. 102:2000;2983-2989.
40. Stampfer M.J., Golditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20:1991;47-63.
41. Swaery G.T., Vita J.A., Keaney J.F. Antioxidant protection of LDL by physiological concentrations of 17-β estradiol. Circulation. 95:1997;1378-1385.
42. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., Shah A.S., Anderson P.W. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 279:1998;1445-1451.
43. Walsh B.W., Paul S., Wild R.A., Dean R.A., Tracy R.P., Cox D.A., Anderson P.W. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 85(1):2000;214-218.
44. Walsh B.W., Cox D.A., Sashegyi A., Dean R.A., Tracy R.P., Anderson P.W. Role of tumor necrosis factor-a and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am. J. Cardiol. 88:2001;825-828.
45. Weiner C.P., Lizosoain I., Baylis S.A., Knowles R.G., Charles I.G., Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc. Natl. Acad. Sci. 91:1994;5212-5216.
46. Williams J.K., Honore E.K., Washburn S.A., Clarkson T.B. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomologus monkeys. J. Am. Coll. Cardiol. 24:1994;1757-1761.
47. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 288(3):2002;321-333.
48. Yang N.N., Venugopalan M., Hardikar S., Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science. 273:1996;1222-1225.
49. Zuckerman S.H., Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis. 126:1996;65-75.